Research graph
References from The convergent roles of metabolic dysfunction, alcohol, and iron in steatotic liver disease: a review. Local targets link to admitted publications; unresolved targets remain external evidence.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
10.1097/hep.0000000000000520 · 2023 · External reference
Non-alcoholic fatty liver disease and alcohol-related liver disease: two intertwined entities
10.3389/fmed.2020.00448 · 2020 · External reference
A new era for steatotic liver disease: evaluating the novel nomenclature in the UK Biobank
10.1016/j.jhep.2023.07.007 · 2024 · External reference
Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States
10.1097/hc9.0000000000000324 · 2023 · External reference
Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017–2020
10.1016/j.cgh.2023.11.003 · 2024 · External reference
Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target
10.1016/j.jhep.2011.05.008 · 2011 · External reference
Liver iron loading in alcohol-associated liver disease
10.1016/j.ajpath.2022.08.010 · 2023 · External reference
The role of alcoholism in hepatic iron storage disease
10.1111/j.1749-6632.1975.tb19149.x · 1975 · External reference
Disorders of iron metabolism
10.1056/nejm199912233412607 · 1999 · External reference
Review on iron and its importance for human health
2014 · External reference
An update on iron physiology
10.3748/wjg.15.4617 · 2009 · External reference
Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005
10.1017/s1368980008002401 · 2009 · External reference
Regulation of cellular iron metabolism
10.1042/bj20101825 · 2011 · External reference
Iron absorption: molecular and pathophysiological aspects
10.3390/metabo14040228 · 2024 · External reference
Cross-link between type 2 diabetes mellitus and iron deficiency anemia. a mini-review
10.1016/j.nutos.2022.08.006 · 2022 · External reference
A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation
10.1016/s1097-2765(00)80425-6 · 2000 · External reference
Hepcidin-ferroportin interaction controls systemic iron homeostasis
10.3390/ijms22126493 · 2021 · External reference
Transferrin and transferrin receptors update
10.1016/j.freeradbiomed.2018.06.037 · 2019 · External reference
Duodenal mRNA expression of iron related genes in response to iron loading and iron deficiency in four strains of mice
10.1136/gut.51.5.648 · 2002 · External reference
The molecular biology of human iron metabolism
10.1309/lmf28s2gimxnwhmm · 2014 · External reference
Proteins of iron homeostasis
10.1007/978-1-60327-485-2_1 · 2012 · External reference
Coordination of iron homeostasis by bone morphogenetic proteins: current understanding and unanswered questions
10.1002/dvdy.372 · 2022 · External reference
Hemojuvelin and bone morphogenetic protein (BMP) signaling in iron homeostasis
10.3389/fphar.2014.00104 · 2014 · External reference
Liver iron sensing and body iron homeostasis
10.1182/blood-2018-06-815894 · 2019 · External reference
The serine protease TMPRSS6 is required to sense iron deficiency
10.1126/science.1157121 · 2008 · External reference
Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia
10.1182/blood-2015-07-658419 · 2015 · External reference
Regulation of iron homeostasis by hepatocyte TfR1 requires HFE and contributes to hepcidin suppression in β-thalassemia
10.1182/blood.2022017811 · 2023 · External reference
Transferrin receptors TfR1 and TfR2 bind transferrin through differing mechanisms
10.1021/acs.biochem.8b00006 · 2018 · External reference
TMPRSS6 as a therapeutic target for disorders of erythropoiesis and iron homeostasis
10.1007/s12325-022-02421-w · 2023 · External reference
From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease
10.1016/j.jlr.2023.100485 · 2024 · External reference
Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort
10.1136/gutjnl-2021-325724 · 2022 · External reference
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
10.1007/s12072-023-10543-8 · 2023 · External reference
Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American heart association
10.1161/atv.0000000000000153 · 2022 · External reference
Mitochondria matter: systemic aspects of nonalcoholic fatty liver disease (NAFLD) and diagnostic assessment of liver function by stable isotope dynamic breath tests
10.3390/ijms22147702 · 2021 · External reference
PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease
10.1055/s-0033-1358525 · 2013 · External reference
Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease
10.1053/j.gastro.2016.01.037 · 2016 · External reference
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
10.1038/ng.257 · 2008 · External reference
Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes
10.1016/j.ajhg.2008.09.012 · 2008 · External reference
Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease
10.1002/hep.24283 · 2011 · External reference
Nonalcoholic fatty liver disease
10.1016/j.bpg.2010.08.005 · 2010 · External reference
A protein-truncating HSD17B13 variant and protection from chronic liver disease
10.1056/nejmoa1712191 · 2018 · External reference
Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease
10.1038/ng.2901 · 2014 · External reference
Liver steatosis, gut-liver axis, microbiome and environmental factors. a never-ending bidirectional cross-talk
10.3390/jcm9082648 · 2020 · External reference
The role of microbiota in nonalcoholic fatty liver disease
10.1111/eci.13768 · 2022 · External reference
Gut microbiota and metabolic dysfunction-associated steatotic liver disease
10.3390/antiox13111386 · 2024 · External reference
Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance
10.1038/s41598-018-19753-9 · 2018 · External reference
The gut microbiota and nonalcoholic fatty liver disease
10.1055/s-0035-1562946 · 2015 · External reference
Human gut microbiome viewed across age and geography
10.1038/nature11053 · 2012 · External reference
Short chain fatty acids in human gut and metabolic health
10.3920/bm2020.0057 · 2020 · External reference
Antibiotics in early life alter the murine colonic microbiome and adiposity
10.1038/nature11400 · 2012 · External reference
Iron and diabetes risk
10.1016/j.cmet.2013.02.007 · 2013 · External reference
Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus
10.1016/0026-0495(88)90023-6 · 1988 · External reference
The role of visceral and subcutaneous adipose tissue fatty acid composition in liver pathophysiology associated with NAFLD
10.4161/21623945.2014.978662 · 2015 · External reference
Pathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity
10.1111/apt.17930 · 2024 · External reference
Insulin resistance in development and progression of nonalcoholic fatty liver disease
10.4291/wjgp.v7.i2.211 · 2016 · External reference
The clinical and histological characteristics of patients with biopsy-proven non-alcoholic fatty liver disease in the absence of insulin resistance
10.14744/hf.2020.2020.0018 · 2020 · External reference
Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial
10.1038/s43856-025-00796-9 · 2025 · External reference
The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population
10.1186/1471-230x-6-33 · 2006 · External reference
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data
10.1371/journal.pone.0030325 · 2012 · External reference
Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors
10.1053/j.gastro.2009.06.005 · 2009 · External reference
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis
10.1016/s2468-1253(20)30357-5 · 2021 · External reference
Current concepts and management approaches in nonalcoholic fatty liver disease
10.1155/2013/481893 · 2013 · External reference
Characteristics and diagnosis of NAFLD/NASH
10.1111/jgh.12271 · 2013 · External reference
High-intensity aerobic exercise improves both hepatic fat content and stiffness in sedentary obese men with nonalcoholic fatty liver disease
10.1038/srep43029 · 2017 · External reference
Therapeutic approaches for non-alcoholic steatohepatitis
10.1177/20420188211034300 · 2021 · External reference
Phase 3 trial of semaglutide in metabolic dysfunction–associated steatohepatitis
10.1056/nejmoa2413258 · 2025 · External reference
Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials
10.7759/cureus.71366 · 2024 · External reference
The emerging role of glucagon-like peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis
10.1016/j.cgh.2024.01.032 · 2024 · External reference
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
10.1056/nejmoa2309000 · 2024 · External reference
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
10.1016/s0140-6736(18)31785-9 · 2018 · External reference
Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH
10.1056/nejmoa2304286 · 2023 · External reference
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
10.1038/s41591-021-01425-3 · 2021 · External reference
A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH
10.1056/nejmoa2036205 · 2021 · External reference
Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease
10.1111/apt.16596 · 2021 · External reference
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design
10.1016/j.cct.2008.09.003 · 2009 · External reference
Metabolic dysfunction–associated steatotic liver disease
10.1056/nejmra2412865 · 2025 · External reference
A critical evaluation of the role of iron overload in fatty liver disease
10.1111/jgh.15971 · 2022 · External reference
Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis
10.1016/j.freeradbiomed.2011.10.003 · 2012 · External reference
CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease
10.1053/jhep.2003.50342 · 2003 · External reference
Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis
10.1158/1055-9965.epi-08-0725 · 2009 · External reference
Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis
10.1111/j.1572-0241.2001.04052.x · 2001 · External reference
Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
10.1016/s0016-5085(98)70482-2 · 1998 · External reference
Serum markers of iron metabolism in chronic liver diseases
10.3889/oamjms.2018.251 · 2018 · External reference
Serum ferritin level is associated with liver steatosis and fibrosis in Korean general population
10.1007/s12072-018-9892-8 · 2019 · External reference
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease
10.1002/hep.24706 · 2012 · External reference
Correlation between serum ferritin level and histopathological disease severity in non-alcoholic fatty liver disease
10.15171/mejdd.2018.96 · 2018 · External reference
Altered lipid metabolism in HFE-knockout mice promotes severe NAFLD and early fibrosis
10.1152/ajpgi.00150.2011 · 2011 · External reference
Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease
10.1089/met.2010.0121 · 2011 · External reference
Pathways underlying iron accumulation in human nonalcoholic fatty liver disease
10.1093/ajcn/87.5.1374 · 2008 · External reference
Serum hepcidin levels are associated with obesity but not liver disease
10.1002/oby.20403 · 2014 · External reference
Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH
10.1053/j.gastro.2006.07.007 · 2006 · External reference
Serum hepcidin levels and iron metabolism in obese children with and without fatty liver: case-control study
10.1007/s00431-014-2268-8 · 2014 · External reference
Interplay of adipocyte and hepatocyte: leptin upregulates hepcidin
10.1016/j.bbrc.2017.11.103 · 2018 · External reference
Matriptase-2 deficiency protects from obesity by modulating iron homeostasis
10.1038/s41467-018-03853-1 · 2018 · External reference
Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis
10.1182/blood-2012-07-440743 · 2012 · External reference
Overexpression of hepcidin alleviates steatohepatitis and fibrosis in a diet-induced nonalcoholic steatohepatitis
10.14218/jcth.2021.00289 · 2022 · External reference
Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease
10.1111/apt.12255 · 2013 · External reference
Iron depletion in “metabolic fatty liver syndromes”: a strong biological rationale with disappointing liver outcomes
10.37349/eds.2023.00016 · 2023 · External reference
A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia
10.3748/wjg.v20.i11.3002 · 2014 · External reference
The impact of phlebotomy in nonalcoholic fatty liver disease: a prospective, randomized, controlled trial
10.1002/hep.27662 · 2015 · External reference
Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel consensus statement
10.1038/s41575-024-00936-x · 2024 · External reference
Current and emerging therapies for alcohol-associated hepatitis
10.1016/j.livres.2023.03.002 · 2023 · External reference
Alcohol-associated liver disease
10.1172/jci176345 · 2024 · External reference
Alcohol-associated hepatitis
10.1056/nejmra2207599 · 2022 · External reference
Alcoholic liver disease: pathogenesis and new therapeutic targets
10.1053/j.gastro.2011.09.002 · 2011 · External reference
Pathogenesis of alcohol-associated liver disease
10.1016/j.jceh.2022.05.004 · 2022 · External reference
Interaction between fatty acid oxidation and ethanol metabolism in liver
10.1152/ajpgi.00281.2023 · 2024 · External reference
Inflammatory pathways in alcoholic steatohepatitis
10.1016/j.jhep.2018.10.023 · 2019 · External reference
Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells
10.1002/hep.24341 · 2011 · External reference
Managing medicines in alcohol-associated liver disease: a practical review
10.18773/austprescr.2021.015 · 2021 · External reference
Non-invasive diagnosis and biomarkers in alcohol-related liver disease
10.1016/j.jhep.2018.11.025 · 2019 · External reference
Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease
10.3748/wjg.v21.i39.11044 · 2015 · External reference
Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease
10.1016/j.jhep.2016.11.011 · 2017 · External reference
Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis
10.1016/j.cgh.2022.11.033 · 2023 · External reference
Nutritional support for alcoholic liver disease
10.3390/nu15061360 · 2023 · External reference
Management of alcohol-related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines
10.1111/liv.15221 · 2022 · External reference
Prednisolone or pentoxifylline for alcoholic hepatitis
10.1056/nejmoa1412278 · 2015 · External reference
Living donor liver transplant for alcohol-associated hepatitis: considerations and global perspectives
10.1080/17474124.2025.2495824 · 2025 · External reference
Emerging pharmacotherapies in alcohol-associated hepatitis
10.1016/j.jceh.2022.06.012 · 2023 · External reference
Interleukin-1 inhibition facilitates recovery from liver injury and promotes regeneration of hepatocytes in alcoholic hepatitis in mice
10.1111/liv.13430 · 2017 · External reference
IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice
10.1172/jci60777 · 2012 · External reference
Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis
10.1002/hep.23167 · 2009 · External reference
Roles for chemokines in liver disease
10.1053/j.gastro.2014.06.043 · 2014 · External reference
Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis
10.1007/s12664-018-0859-4 · 2018 · External reference
Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study
10.1016/j.cgh.2016.10.029 · 2017 · External reference
Granulocyte colony-stimulating factor for alcoholic hepatitis: a systematic review and meta-analysis of randomised controlled trials
10.1016/j.jhepr.2020.100139 · 2020 · External reference
Interleukin 22 in liver injury, inflammation and cancer
10.7150/ijbs.38925 · 2020 · External reference
Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression
10.1074/jbc.m602098200 · 2006 · External reference
Induction of transferrin receptor by ethanol in rat primary hepatocyte culture
10.1111/j.1530-0277.2004.tb03225.x · 2004 · External reference
Iron overload in alcoholic liver disease: underlying mechanisms, detrimental effects, and potential therapeutic targets
10.1007/s00018-022-04239-9 · 2022 · External reference
Liver iron loading in alcohol-associated liver disease
10.1016/j.ajpath.2022.08.010 · 2023 · External reference
Effects of chronic alcohol and excessive iron intake on mitochondrial DNA damage in the rat liver
10.4163/jnh.2015.48.5.390 · 2015 · External reference
Ferroptosis in liver disease: new insights into disease mechanisms
10.1038/s41420-021-00660-4 · 2021 · External reference
Ferroptosis contributes to ethanol-induced hepatic cell death via labile iron accumulation and GPx4 inactivation
10.1038/s41420-023-01608-6 · 2023 · External reference
Ferroptosis is involved in alcohol-induced cell death in vivo and in vitro
10.1080/09168451.2020.1763155 · 2020 · External reference
Advancements in the alcohol-associated liver disease model
10.3390/biom12081035 · 2022 · External reference
Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis
10.1136/gutjnl-2020-322509 · 2021 · External reference
Damage-associated molecular pattern–activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury
10.1002/hep.27841 · 2015 · External reference
Excess iron into hepatocytes is required for activation of collagen type I gene during experimental siderosis
10.1016/0016-5085(94)90237-2 · 1994 · External reference
Liver fibrosis leading to cirrhosis: basic mechanisms and clinical perspectives
10.3390/biomedicines12102229 · 2024 · External reference
Serum ferritin and transferrin saturation in patients with chronic alcoholic and non-alcoholic liver diseases
10.1111/j.1365-2796.1994.tb00802.x · 1994 · External reference
In alcoholic cirrhosis, low-serum hepcidin levels associate with poor long-term survival
10.1111/liv.13007 · 2016 · External reference
Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial
10.1093/jnci/djn209 · 2008 · External reference
Metabolic and alcohol-associated liver disease (MetALD): a representation of duality
10.1038/s44355-024-00014-8 · 2025 · External reference
A cohort study of the effect of alcohol consumption and obesity on serum liver enzyme levels
10.1097/meg.0b013e3283328b86 · 2010 · External reference
Harmful effect of adipose tissue on liver lesions in patients with alcoholic liver disease
10.1016/j.jhep.2010.01.029 · 2010 · External reference
Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus
10.1016/j.metabol.2020.154439 · 2021 · External reference
Prevalence of and risk factors for hepatic steatosis in Northern Italy
10.7326/0003-4819-132-2-200001180-00004 · 2000 · External reference
Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD
10.1016/j.jhep.2023.08.021 · 2024 · External reference
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
10.1038/s41575-023-00822-y · 2023 · External reference
MASLD is related to impaired alcohol dehydrogenase (ADH) activity and elevated blood ethanol levels: role of TNFα and JNK
10.1016/j.redox.2024.103121 · 2024 · External reference
Alcohol metabolism in the progression of human nonalcoholic steatohepatitis
10.1093/toxsci/kfy106 · 2018 · External reference
Roles of hormonal and nutritional factors in the regulation of rat liver alcohol dehydrogenase activity and ethanol elimination rate in vivo
10.1111/j.1530-0277.1988.tb00217.x · 1988 · External reference
Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease
10.1136/gutjnl-2014-308379 · 2016 · External reference
Association of serum retinoic acid with hepatic steatosis and liver injury in nonalcoholic fatty liver disease
10.3945/ajcn.114.105155 · 2015 · External reference
The role of alcohol dehydrogenase in drug metabolism: beyond ethanol oxidation
10.1208/s12248-020-00536-y · 2021 · External reference
CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease
10.1016/j.jhep.2012.08.018 · 2013 · External reference
Comparison of self-reported alcohol consumption and ethyl glucuronide in hair in a sample of 60+ year-olds treated for DSM-5 alcohol use disorder
10.1111/adb.13231 · 2022 · External reference
Ethyl glucuronide—the direct ethanol metabolite on the threshold from science to routine use
10.1046/j.1359-6357.2003.00588.x · 2003 · External reference
Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD
10.1097/hc9.0000000000000003 · 2023 · External reference
Blood biomarkers of alcohol use: a scoping review
10.1007/s40429-021-00402-7 · 2021 · External reference
Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease
10.1016/j.jhep.2024.06.036 · 2024 · External reference
Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality
10.1002/hep.32642 · 2023 · External reference
Natural history of metabolic dysfunction-associated steatotic liver disease
10.1016/j.ejim.2023.11.005 · 2024 · External reference
Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease
10.1016/j.cgh.2018.11.033 · 2019 · External reference
Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis
10.1016/j.cgh.2018.01.026 · 2018 · External reference
Experimental liver cirrhosis induced by alcohol and iron
10.1172/jci118077 · 1995 · External reference
Excessive intake of fructose and alcohol aggravates high-fat diet-induced steatohepatitis and changes hepatic iron homeostasis
10.1007/s00418-025-02402-4 · 2025 · External reference
Alcohol activates TGF-beta but inhibits BMP receptor-mediated Smad signaling and Smad4 binding to hepcidin promoter in the liver
10.1155/2012/459278 · 2012 · External reference
Is the iron regulatory hormone hepcidin a risk factor for alcoholic liver disease?
10.3748/wjg.15.1186 · 2009 · External reference
Serum ferritin concentration predicts mortality in patients awaiting liver transplantation
10.1002/hep.23537 · 2010 · External reference
